Translator Disclaimer
4 December 1996 In vitro phototoxicity of a new phthalocyanine-immunoconjugate for use in photodynamic therapy
Author Affiliations +
Non specific localization of photosensitizers after application in vivo limits progress in PDT. Relatively selective distribution of photosensitizers in malignant tissues is crucial for a successful treatment. The target specificity of photosensitizers may be improved by linking photosensitizers with monoclonal antibodies. In this approach, a high specific monoclonal antibody, BM-2 which is directed against epitopes of the mucine glycoprotein TAG-12 was used. This antibody shows reactivity with 96% of all primary breast carcinomas. BM-2 was conjugated with a second generation phthalocyanine photosensitizer which is only weakly phototoxic to human T-47D tumor cells without conjugation in vitro. With respect to future clinical application, illumination times from 25 to 100 minutes and a powerful diode laser with an emission of 690 nm was chosen, which provides deeper tissue penetration in vivo. We observed phototoxicity towards T-47D human breast carcinoma cells at concentrations ranging from 0.25 to 6 micromol/L and light doses from 6 to 24 J/cm2. The immunoconjugates discriminated mucine-positive and mucine-negative tumor cells and showed high photocytotoxic selectivity towards mucine-positive T-47D cells in vitro. The conjugate showed no dark toxicity. In vivo experiments will follow.
© (1996) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Michael Martin, Sepp Kaul, Ute Drechsler, M. Geyer, R. Kurek, Michael Hanack, Stefan Seeger, D. Wallwiener M.D., and Juergen M. Wolfrum "In vitro phototoxicity of a new phthalocyanine-immunoconjugate for use in photodynamic therapy", Proc. SPIE 2924, Photochemotherapy: Photodynamic Therapy and Other Modalities II, (4 December 1996);

Back to Top